BioCentury
ARTICLE | Clinical News

Tarextumab: Development discontinued

April 21, 2017 8:33 PM UTC

OncoMed said it will discontinue all clinical development of tarextumab after reporting data from 145 previously untreated patients with extensive-stage SCLC in the Phase II portion of the double-blin...

BCIQ Company Profiles

OncoMed Pharmaceuticals Inc.